{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:19:02Z","timestamp":1787797142008,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada ULC","doi-asserted-by":"publisher","award":["75336983"],"award-info":[{"award-number":["75336983"]}],"id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vaccine.2026.128977","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:55:32Z","timestamp":1786049732000},"page":"128977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical features and outcomes of pediatric breakthrough invasive pneumococcal disease (IPD) in vaccinated children in Calgary, Alberta, Canada, 2003\u20132024"],"prefix":"10.1016","volume":"90","author":[{"given":"Emily J.","family":"Doucette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah J.","family":"Ricketson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Murgu\u00eda-Favela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128977_bb0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41579-024-01116-z","article-title":"Streptococcus pneumoniae epidemiology, pathogenesis and control","volume":"23","author":"Narciso","year":"2025","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128977_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00175-24","article-title":"Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward","volume":"38","author":"Ganaie","year":"2025","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128977_bb0015","doi-asserted-by":"crossref","first-page":"e266005","DOI":"10.1001\/jamanetworkopen.2026.6005","article-title":"Invasive pneumococcal disease epidemiology and conjugate vaccines in Canada, 2000-2019","volume":"9","author":"Ramos","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128977_bb0020","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.vaccine.2022.03.048","article-title":"Canadian Immunization Monitoring Program, Active (IMPACT) investigators. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: an IMPACT study","volume":"40","author":"Ricketson","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128977_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/INF.0000000000001709","article-title":"Changes in the nature and severity of invasive pneumococcal disease in children before and after the seven-valent and thirteen-valent pneumococcal conjugate vaccine programs in Calgary","volume":"37","author":"Ricketson","year":"2018","journal-title":"Canada Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1086\/599827","article-title":"Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study","volume":"49","author":"Kellner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128977_bb0035","unstructured":"Public Health Agency of Canada. Pneumococcal vaccines: Canadian Immunization Guide, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-16-pneumococcal-vaccine.html; 2025 [accessed 10 September 2025]."},{"key":"10.1016\/j.vaccine.2026.128977_bb0040","unstructured":"Alberta Health. Alberta Immunization Program History, https:\/\/open.alberta.ca\/dataset\/aip\/resource\/ad8b789a-5f23-4e52-b634-f10c9bda9a02\/download\/AIP-Alberta-Vaccine-Program-Changes.pdf; 2025 [accessed 12 September 2025]."},{"issue":"5","key":"10.1016\/j.vaccine.2026.128977_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11051333","article-title":"Changes in the incidence of invasive pneumococcal disease in Calgary, Canada, during the SARS-CoV-2 pandemic 2020-2022","volume":"11","author":"Ricketson","year":"2023","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e3182788fdd","article-title":"Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine","volume":"32","author":"Sharma","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"9807","key":"10.1016\/j.vaccine.2026.128977_bb0055","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128977_bb0060","article-title":"Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review","volume":"11","author":"Feemster","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128977_bb0065","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/cid\/cix418","article-title":"Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006\u20132014","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128977_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128977_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128977_bb0080","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/INF.0000000000003554","article-title":"Screening for immunodeficiencies in children with invasive pneumococcal disease: six-year experience from a UK children\u2019s hospital","volume":"41","author":"Bijker","year":"2022","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128977_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/INF.0000000000004004","article-title":"Inborn errors of immunity in children with invasive pneumococcal disease: a multicenter prospective study","volume":"42","author":"Phuong","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cid\/ciu274","article-title":"Invasive pneumococcal disease in children can reveal a primary immunodeficiency","volume":"59","author":"Gaschignard","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128977_bb0095","article-title":"Immunodeficiency in children with invasive pneumococcal disease","volume":"17","author":"Almesfer","year":"2025","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0100","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1155\/2014\/196748","article-title":"Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta","volume":"25","author":"Ricketson","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"9546","key":"10.1016\/j.vaccine.2026.128977_bb0105","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128977_bb0110","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/INF.0000000000000076","article-title":"Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers","volume":"33 Suppl 2","author":"Whitney","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128977_bb0115","unstructured":"Alberta Health. Immunization and routine immunization schedule, https:\/\/www.alberta.ca\/immunization-routine-schedule; 2025 [accessed 1 April 2026]."},{"issue":"50","key":"10.1016\/j.vaccine.2026.128977_bb0120","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1016\/j.vaccine.2016.10.050","article-title":"Pneumococcal conjugate vaccine failure in children: a systematic review of the literature","volume":"34","author":"Oligbu","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14760584.2022.2012455","article-title":"A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children","volume":"21","author":"Mungall","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128977_bb0130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128977_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1014065","article-title":"What is driving the resurgence and persistence of vaccine-targeted pneumococcal serotypes? \u2014 Serotype 19F as the paradigm","volume":"22","author":"Thindwa","year":"2026","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128977_bb0140","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.17269\/CJPH.108.5885","article-title":"Timeliness and completeness of routine childhood vaccinations in children by two years of age in Alberta, Canada","volume":"108","author":"Saini","year":"2017","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2026.128977_bb0145","unstructured":"Alberta Health. Alberta childhood immunization coverage dashboard - time trends, Calgary Zone. Alberta Interactive Health Data Application, http:\/\/www.ahw.gov.ab.ca\/IHDA_Retrieval\/ihdaGeographic.do#; 2025 [accessed 3 October 2025]."},{"key":"10.1016\/j.vaccine.2026.128977_bb0150","unstructured":"Public Health Agency of Canada. Vaccination Coverage Goals and Vaccine Preventable Disease Reduction Targets by 2025, https:\/\/www.canada.ca\/en\/public-health\/services\/immunization-vaccine-priorities\/national-immunization-strategy\/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html#1.1.2; 2022 [accessed 3 October 2025]."},{"key":"10.1016\/j.vaccine.2026.128977_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128065","article-title":"Pneumococcal vaccines: a dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019\u20132024)","volume":"72","author":"Dambre","year":"2026","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128977_bb0160","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/thorax-2025-223125","article-title":"Serotype 3 associated invasive pneumococcal disease in children: analysis of 15 years of Australian national surveillance data","volume":"80","author":"Homaira","year":"2025","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128977_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01077-22","article-title":"Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016\u20132019)","volume":"10","author":"Silva-Costa","year":"2022","journal-title":"Microbiol Spectrum"},{"key":"10.1016\/j.vaccine.2026.128977_bb0170","first-page":"e279","article-title":"Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era","volume":"148","author":"Izquierdo","year":"2020","journal-title":"Epidemiol Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128977_bb0175","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2025-073196","article-title":"Pneumococcal pneumonia in hospitalized children: 2017-2023","volume":"157","author":"Engstrom","year":"2026","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128977_bb0180","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0836","article-title":"Pneumococcal conjugate vaccine breakthrough infections: 2001\u20132016","volume":"145","author":"Adebanjo","year":"2020","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128977_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites: e1001517","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128977_bb0190","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/eurpub\/ckw089","article-title":"Pneumococcal pneumonia vaccine breakthroughs and failures after 13-valent pneumococcal conjugated vaccine","volume":"26","author":"Almeida","year":"2016","journal-title":"Eur J Pub Health"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128977_bb0195","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cix895","article-title":"Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries","volume":"66","author":"Voysey","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128977_bb0200","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128977_bb0205","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1016\/j.vaccine.2023.07.049","article-title":"Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada","volume":"41","author":"Deceuninck","year":"2023","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128977_bb0210","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study","volume":"42","author":"Andrejko","year":"2024","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2026.128977_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14745\/ccdr.v50i12a04","article-title":"PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity?","volume":"50","author":"De Wals","year":"2024","journal-title":"Can Commun Dis Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128977_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:11:09Z","timestamp":1787796669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0264410X26007863"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128977","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and outcomes of pediatric breakthrough invasive pneumococcal disease (IPD) in vaccinated children in Calgary, Alberta, Canada, 2003\u20132024","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128977"}}